ET 019003 / Eureka Therap - LARVOL DELTA

Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma. (PubMed, J Hematol Oncol) - P1 | "CD19-specific γ/δ TCR-T cells, ET019003, had a good safety profile and could induce rapid responses and durable CR in patients with relapsed or refractory DLBCL, even primary CNS lymphoma, presenting a novel and potent therapeutic option for these patients."

Journal • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Immune Modulation • Inflammation • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19

Novel CD19-Specific γ/δ TCR-T Cells in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (ASH 2021) - P1 | "We previously developed a human anti-CD19 antibody (ET190L1), and found that ET190L1-TCR-T cells maintained comparable anti-tumor potency with less cytokine release to CD28-costimulated ET190L1-CAR and CD137-based CTL019 T cells (Cell Discov...Cyclophosphamide 250 mg/m 2 on day -5 and fludarabine 25 mg/m 2 on day -5 to -3 were used as the conditioning regimen... These data suggest ET019003-T cells had a good safety profile and could induce durable remission in patients with RR DLBCL, even with primary CNS lymphoma. γ/δ TCR-T cells may present a potential therapeutic option for these patients."

IO biomarker • Anemia • CNS Disorders • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Immune Modulation • Infectious Disease • Inflammation • Lymphoma • Movement Disorders • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Respiratory Diseases • Thrombocytopenia • BCL2 • BCL6 • CD19 • IL6 • MYC • TNFRSF9

A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma. (PubMed, J Cancer Res Clin Oncol) - P1 | "This study provides initial clinical validation of the AbTCR platform as a novel cancer treatment with the potential to provide durable clinical benefit with low toxicity."

Journal • Hematological Malignancies • Immune Modulation • Inflammation • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19

ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and Lymphoma (clinicaltrials.gov) - P1; N=9; Active, not recruiting; Sponsor: Wuhan Union Hospital, China; Recruiting ➔ Active, not recruiting; N=18 ➔ 9

Clinical • Enrollment change • Enrollment closed • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19

First-in-Human Study of ET019003, a Next Generation Anti-CD19 T-Cell Therapy, in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL) (ASH 2019) - "Following a 3-day preconditioning treatment with Fludarabine (25mg/m2/day)/ Cyclophosphamide (250mg/m2/day), patients received i.v. infusions of ET019003 T cells at an initial dose of 2-3×106 cells/kg. Preliminary results from six CD19+ r/r DLBCL patients in a FIH study show that ET019003 T-cell therapy is safe with robust in vivo T-cell expansion. The clinical study is on-going and we are monitoring safety as well as duration of response in longer follow-up. Reference: Xu et al."

Clinical • IO biomarker • P1 data • CNS Disorders • Diffuse Large B Cell Lymphoma • Epilepsy • Hematological Disorders • Hematological Malignancies • Herpes Zoster • Immune Modulation • Inflammation • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Thrombocytopenia • Varicella Zoster

Dr. Solomon on the Effects of Liso-Cel in Prior Anti-CD19 Therapy–Treated B-NHL (OncLive) - P1, N=12; TRANSCEND NHL 001 (NCT02631044); Sponsor: Juno Therapeutics, a Subsidiary of Celgene; "Scott R. Solomon, MD...discusses the effects of lisocabtagene maraleucel (liso-cel; Breyanzi) in patients with relapsed/refractory large B-cell non-Hodgkin lymphoma (B-NHL) who were previously treated with CD19-directed therapies....As such, these data suggest that prior exposure to CD19-directed therapy does not negatively affect the efficacy of liso-cel in this patient population, concludes Solomon."

P1 data • Video

Safety and Efficiency Study of ET019003-T Cells in Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma (clinicaltrials.gov) - P1; N=18; Recruiting; Sponsor: Wuhan Union Hospital, China; N=50 ➔ 18

Clinical • Enrollment change • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19

Eureka Therapeutics to present new clinical data of anti-CD19 ARTEMIS 3.0 T-cell therapy at 2019 ASH Annual Meeting (Businesswire) - "Eureka Therapeutics, Inc...announced that new clinical data from its first-in-human study of ET019003, an anti-CD19 T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL), will be presented in a poster session at the 61st American Society of Hematology (ASH) Annual Meeting on December 8, 2019."

Clinical data